周一，Cassava Sciences经历了市场情绪的重大转变，Rodman & Renshaw将该公司股票评级从买入下调至卖出，目标价从之前的107.00美元大幅调整至2.00美元。此次降级紧随Cassava宣布其针对阿尔茨海默病潜在治疗药物simufilam的3期ReThink-ALZ研究未能达到关键终点。

智通财经APP获悉，周一，Cassava Sciences (SAVA.US)股价暴跌，截至发稿，该股跌超84%，报4.06美元。该公司表示，其simufilam治疗轻度至中度阿尔茨海默症的3期ReThink-ALZ研究的初步结果没有达到预先设定的共同主要终点、次要终点和探索性生物标志物终点。

，周一，Cassava Sciences(SAVA.US)股价暴跌，截至发稿，该股跌超84%，报4.06美元。该公司表示 ，周一，Cassava Sciences(SAVA.US)股价暴跌，截至发稿，该股跌超84%，报4.06美元。该公司表示，其simufilam治疗轻度至中度阿尔茨海默症的3期ReThink-ALZ研究的初步结果没有达到预先设定的共同主要终点、次要终点和探索性生物标志物终点。 该 ...

周一，在Cassava Sciences (NASDAQ:SAVA)公布其针对阿尔茨海默病的RETHINK-ALZ三期临床试验结果后，Jones Trading重申了对该公司股票的"持有"评级。根据最近的新闻稿，该试验未能达到其共同主要终点。这项包括轻度和中度阿尔茨海默病患者亚组的分析显示，在第52周时，两个主要终点均未达到统计学显著性。

Cassava Sciences (SAVA) shares are cratering by over 80% on Monday after the pharmaceutical company failed to meet its latest ...

Cassava Sciences Inc.’s stock tumbled 85% Monday to put it on track for its biggest-ever one-day decline, after the ...

The Cassava Sciences story ended Monday exactly as many knew it would — with the company’s experimental drug for Alzheimer’s ...

Cassava Sciences Inc. (NASDAQ:SAVA) stock plunged Monday after the company released topline data from the Phase 3 ReThink-ALZ ...

Cassava Sciences stock plummeted Monday after the company's Alzheimer's treatment failed in Phase 3 testing. Billionaire Ken ...

Cassava Sciences (NASDAQ:SAVA) stock has plummeted ~86% after announcing that Alzheimer's disease candidate simufilam did ...

EST Cassava Sciences (SAVA) sinks 84% to $4.21 after Alzheimer’s study missDon't Miss our Black Friday Offers:Unlock your investing ...

Cassava Sciences (SAVA) announced that the topline results from the Phase 3 ReThink-ALZ study of simufilam in mild-to-moderate AD did not meet ...